199 related articles for article (PubMed ID: 26314506)
1. MiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4.
Li J; Meng H; Cao W; Qiu T
Neurosci Lett; 2015 Oct; 606():167-72. PubMed ID: 26314506
[TBL] [Abstract][Full Text] [Related]
2. MiR-155 is involved in major depression disorder and antidepressant treatment via targeting SIRT1.
Wang X; Wang B; Zhao J; Liu C; Qu X; Li Y
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30482883
[TBL] [Abstract][Full Text] [Related]
3. A genetic variant in miRNA binding site of glutamate receptor 4, metabotropic (GRM4) is associated with increased risk of major depressive disorder.
Dadkhah T; Rahimi-Aliabadi S; Jamshidi J; Ghaedi H; Taghavi S; Shokraeian P; Akhavan-Niaki H; Tafakhori A; Ohadi M; Darvish H
J Affect Disord; 2017 Jan; 208():218-222. PubMed ID: 27792966
[TBL] [Abstract][Full Text] [Related]
4. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment.
Lopez JP; Lim R; Cruceanu C; Crapper L; Fasano C; Labonte B; Maussion G; Yang JP; Yerko V; Vigneault E; El Mestikawy S; Mechawar N; Pavlidis P; Turecki G
Nat Med; 2014 Jul; 20(7):764-8. PubMed ID: 24908571
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Expression of Intracellular let-7e, miR-146a, and miR-155 Correlates with Severity of Depression in Patients with Major Depressive Disorder and Is Ameliorated after Antidepressant Treatment.
Hung YY; Wu MK; Tsai MC; Huang YL; Kang HY
Cells; 2019 Jun; 8(7):. PubMed ID: 31252530
[TBL] [Abstract][Full Text] [Related]
6. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder.
He S; Liu X; Jiang K; Peng D; Hong W; Fang Y; Qian Y; Yu S; Li H
J Psychiatr Res; 2016 Jul; 78():65-71. PubMed ID: 27078210
[TBL] [Abstract][Full Text] [Related]
7. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment.
Muguruza C; Miranda-Azpiazu P; Díez-Alarcia R; Morentin B; González-Maeso J; Callado LF; Meana JJ
Neuropharmacology; 2014 Nov; 86():311-8. PubMed ID: 25150943
[TBL] [Abstract][Full Text] [Related]
9. Changes in miRNA-132 and miR-124 levels in non-treated and citalopram-treated patients with depression.
Fang Y; Qiu Q; Zhang S; Sun L; Li G; Xiao S; Li X
J Affect Disord; 2018 Feb; 227():745-751. PubMed ID: 29689690
[TBL] [Abstract][Full Text] [Related]
10. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
11. Chipping away at major depressive disorder.
Rucker JJ; McGuffin P
Genome Biol; 2014 Jul; 15(7):421. PubMed ID: 25315250
[TBL] [Abstract][Full Text] [Related]
12. The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder.
Liu W; Zhang F; Zheng Y; He S; Zhang T; Guo Q; Xu H; Chen H; Liu C; Yu S; Jiang K; Li H; Li G; Wang X; Liu X
Neurosci Lett; 2021 Oct; 763():136184. PubMed ID: 34418506
[TBL] [Abstract][Full Text] [Related]
13. Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants.
Chang HS; Won E; Lee HY; Ham BJ; Lee MS
Behav Brain Res; 2015 Oct; 292():116-24. PubMed ID: 26055202
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of child and adolescent depression.
Moreno C; Roche AM; Greenhill LL
Child Adolesc Psychiatr Clin N Am; 2006 Oct; 15(4):977-98, x. PubMed ID: 16952771
[TBL] [Abstract][Full Text] [Related]
15. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
[TBL] [Abstract][Full Text] [Related]
16. Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies.
Artigas F; Celada P; Bortolozzi A
Eur Neuropsychopharmacol; 2018 Apr; 28(4):457-482. PubMed ID: 29525411
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Histone Modification of TNFAIP3, TLR4, TNIP2, miR-146a, and miR-155 in Major Depressive Disorder.
Tseng CC; Wang SC; Yang YC; Fu HC; Chou CK; Kang HY; Hung YY
Mol Neurobiol; 2023 Aug; 60(8):4753-4760. PubMed ID: 37148522
[TBL] [Abstract][Full Text] [Related]
18. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
[TBL] [Abstract][Full Text] [Related]
19. TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder.
Hung YY; Lin CC; Kang HY; Huang TL
Brain Behav Immun; 2017 Jan; 59():265-272. PubMed ID: 27640899
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of glutamate in the pathophysiology of major depressive disorder.
Hashimoto K
Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
